About Us
Greenfire Bio (GFB)
GFB is an oncology focused clinical stage biopharma company that looks to collaborate with, in-license or acquire early-stage assets and develop them through clinical proof-of-concept and beyond. As we access new assets, we set up new subsidiaries to provide the focus required to advance these into and through the clinic.
How we build success
Medical innovations are precious and exciting and come from all over. Making a good idea in medicine into a product is a difficult and expensive process. It requires expertise and capital often not available for startups completing laboratory proof-of-concept.
That’s where Greenfire comes in. We have assembled highly experienced team of pharmaceutical experts bolstered by a network of advisors and service providers to deploy on late pre-clinical and early clinical assets to accelerate their development into products.
Our extensive network seeks out exciting innovations, engages flexibly with innovators, and accelerates the transition to medical products. We take the unappreciated risks out of development – timely access to expertise and capital. If you think you have an innovation that fits our profile, contact us.
status
Since the inception of the company in 2020, the company has acquired a first-in-class small molecule SIK2/3 inhibitor (GRN300) currently in a Ph1 trial, invested in a company called Pacylex that has a first-in-class NMT1/NMT2 inhibitor (PCLX001) in Ph2 testing for hematological malignancies and solid tumors. GFB has set up operating subsidiaries for the SIK2/3 inhibitor (Green3Bio) and the therapeutic vaccine products (MGFB Bio).
Opportunity Access
Capitalize on access to innovative preclinical and early-stage clinical products and technology
Development Acceleration
Leverage an integrated ecosystem of development organizations and internal expertise to accelerate product development timelines
Business MONETIZATION
Monetize investments through strategic and well-timed out-licensing, sale or IPO of each product to provide liquidity to investors and the best path to bringing products to patients
Our process sounds simple but execution is where we excel
Acquire pipeline of differentiated products to meet underserved medical needs. If you think you have an innovation that fits our profile, contact us.
Deploy very experienced biopharma team for efficient drug development and business management
Utilize a successful organizational model; leverage virtual operations focused program management and partner ecosystem of service providers
Exit programs after advancing candidates to an appropriate value inflection point
Provide excellent returns to investors by delivering superior products to patients
MANAGEMENT TEAM
Ajit Gill
CEO, Founder, Director
CEO & President Nektar Therapeutics
VP and Gen Mgr Kodak’s Interactive Systems
VP Finance at TRW-Fujitsu
Sanjeev Munshi, PHD, MBA
PhD, MBA, CBO, Advisor
SVP, BD & Alliance Management, InveniAI
Ex. Director Merck BD and Discovery
Vikas Agarwal, PhD
PhD, Development, Advisor
J. Andrew Sanford
MBA, CFO
Markus Peter
Program Lead, GRN-300
Chris Searcy
PhD, Development, Advisor
BOARD OF DIRECTORS
Ajit Gill
Director
J. Andrew Sanford, MBA
Consultant
Chris Searcy, Consultant, Corporate Development
CBO Nocion
CBO Respira
CBO Taris
VP Valeritas, Nektar, Pfizer
Hong-Min Suh
Chair, M2N
CEO, DK Marine
Chair, The LEADCORP
Sang Hoon Shin
PIPELINE
Making a fast start to building an innovative pipeline, agnostic to therapeutic areas, we are addressing serious unmet medical needs.
If you think you have an innovation that fits our business strategy, contact us.
*Click for more information about portfolio candidates
| Products | Company | Target | Indication | Therapeutic Area | Discovery | Preclinical | Clinical | |||
|---|---|---|---|---|---|---|---|---|---|---|
| In Vitro | In Vivo | Lead Op | IND Enabling | Phase 1 | Phase 2 | |||||